ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-09-14
Target enrollment:
Participant gender:
Summary
This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the
efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients
with advanced non-small cell lung cancer, previously treated with at least one prior regimen.
Analyses of primary objective (Progression Free Survival) will be done in two co-primary
populations as defined in the protocol.